Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
Authors not listed
Genticel · 2015
Abstract
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2015). A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL. <em>Genticel</em>. https://clinicaltrials.gov/study/NCT02689726
Vancouver
Anonymous. A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL. Genticel. 2015.
BibTeX
@misc{anon2015APhase,
title = {A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL},
author = {Anonymous},
journal = {Genticel},
year = {2015},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Yikang Biotech (Suzhou) Co., Ltd. 2026
Open access · US-GOV
A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Guangzhou Patronus Biotech Co., Ltd. 2025
Open access · US-GOV
A Phase Ⅱ, Randomized, Observer-blinded, Parallel-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
Merck Sharp & Dohme LLC 2007
Open access · US-GOV
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients With Sarcopenia
Changchun BCHT Biotechnology Co. 2026
Open access · US-GOV
A Phase I Clinical Trial for Randomized, Blinded, Placebo-Controlled Evaluation of Safety, Tolerability and Preliminary Exploratory Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cell) With Different Doses in Adults Aged 40 Years and Above
Institut de Recherches Internationales Servier 2021
Open access · US-GOV
SPARK-ALL: A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years With Newly-diagnosed Philadelphia-negative ALL.
Alachua Government Services, Inc. 2013
Open access · US-GOV